Beam Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Beam Therapeutics
BEAM Stock  USD 27.62  1.67  5.70%   
Beam Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Beam Therapeutics' valuation are provided below:
Gross Profit
-356.1 M
Market Capitalization
2.8 B
Enterprise Value Revenue
33.7371
Revenue
55.7 M
Earnings Share
(4.41)
There are over one hundred nineteen available fundamental signals for Beam Therapeutics, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Beam Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 1st of February 2026, Market Cap is likely to grow to about 3.8 B. Also, Enterprise Value is likely to grow to about 3.6 B

Beam Therapeutics Total Revenue

87.06 Million

Check Beam Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Beam Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.5 M, Interest Expense of 59.3 M or Selling General Administrative of 134.7 M, as well as many indicators such as Price To Sales Ratio of 35.11, Dividend Yield of 0.0 or PTB Ratio of 2.63. Beam financial statements analysis is a perfect complement when working with Beam Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Beam Stock
Check out the analysis of Beam Therapeutics Correlation against competitors.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Beam Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets846.6 M1.3 B487.6 M
Slightly volatile
Short and Long Term Debt Total125.8 M185.6 M67.7 M
Slightly volatile
Other Current Liabilities66.7 M64.2 M38.2 M
Slightly volatile
Total Current Liabilities135.9 M209.4 M81.1 M
Slightly volatile
Property Plant And Equipment Net145.9 M248.7 M85.8 M
Slightly volatile
Accounts Payable4.4 M3.5 M3.4 M
Slightly volatile
Cash255.5 M324.3 M144.2 M
Slightly volatile
Non Current Assets Total157.9 M259.5 M92.3 M
Slightly volatile
Non Currrent Assets Other11.8 M10.8 M6.4 M
Slightly volatile
Cash And Short Term Investments635.8 M978.4 M367.8 M
Slightly volatile
Common Stock Shares Outstanding60.5 M94.7 M40.3 M
Slightly volatile
Liabilities And Stockholders Equity846.6 M1.3 B487.6 M
Slightly volatile
Non Current Liabilities Total194.9 M216.4 M107.6 M
Slightly volatile
Other Current Assets33.1 M31.5 M8.8 M
Slightly volatile
Other Stockholder Equity2.8 B2.6 B819.2 M
Slightly volatile
Total Liabilities330.8 M425.8 M188.7 M
Slightly volatile
Total Current Assets688.6 M1 B395.4 M
Slightly volatile
Short Term Debt9.3 M15.5 M5.7 M
Slightly volatile
Common Stock516.3 K961.4 K309.9 K
Slightly volatile
Other Liabilities259.5 M247.1 M89.2 M
Slightly volatile
Other Assets14.8 M16.9 M8.4 M
Slightly volatile
Capital Stock714.8 K752.4 K151.2 M
Slightly volatile
Non Current Liabilities Other1.8 M1.9 M3.6 M
Slightly volatile
Net Working Capital632.4 M800.5 M378.8 M
Slightly volatile
Property Plant Equipment282.7 M269.3 M103.7 M
Slightly volatile
Long Term Debt3.4 M2.7 M4 M
Slightly volatile
Short Term Investments507.1 M654.1 M259.9 M
Slightly volatile
Capital Lease Obligations143.2 M185.6 M78.8 M
Slightly volatile
Deferred Long Term Liabilities2.5 M2.8 M3 M
Slightly volatile
Property Plant And Equipment Gross224.7 M331.6 M129.9 M
Slightly volatile
Short and Long Term Debt2.1 M2.6 M1.7 M
Slightly volatile
Common Stock Total Equity547.2 K615.6 K671.9 K
Slightly volatile
Capital Surpluse1.3 B1.4 B1.6 B
Slightly volatile

Beam Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization26.5 M25.2 M7.9 M
Slightly volatile
Selling General Administrative134.7 M128.3 M42 M
Slightly volatile
Other Operating Expenses294.1 M550.9 M178.7 M
Slightly volatile
Research Development233.9 M422.7 M141.1 M
Slightly volatile
Cost Of Revenue211.8 M422.7 M127.9 M
Slightly volatile
Total Operating Expenses142.5 M128.3 M80.4 M
Slightly volatile
Interest Income1.5 M2.9 M1.3 M
Slightly volatile
Reconciled Depreciation38.1 M36.3 M9.4 M
Slightly volatile
Non Operating Income Net Other17.5 M19.6 M21.4 M
Slightly volatile
Selling And Marketing Expenses16 M18 M19.7 M
Slightly volatile

Beam Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation145.7 M138.8 M39 M
Slightly volatile
Other Cashflows From Financing Activities7 M7.4 M17.6 M
Very volatile
Depreciation26.5 M25.2 M7.3 M
Slightly volatile
Capital Expenditures9.8 M10.3 M12 M
Slightly volatile
Total Cash From Financing Activities8.5 M8.9 M103.1 M
Slightly volatile
End Period Cash Flow265.4 M333.6 M149.6 M
Slightly volatile
Begin Period Cash Flow257.8 M511.3 M142.6 M
Slightly volatile
Change To Netincome18.5 M19.5 M66.8 M
Slightly volatile
Dividends Paid10.2 M11.4 M12.5 M
Slightly volatile
Cash And Cash Equivalents Changes316.6 M356.2 M388.7 M
Slightly volatile
Cash Flows Other Operating41.5 M46.7 M51 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio35.1136.9640.8 K
Slightly volatile
Days Sales Outstanding1.7 K1.9 K2.1 K
Slightly volatile
Stock Based Compensation To Revenue2.082.18268
Slightly volatile
Capex To Depreciation0.450.4717.1536
Slightly volatile
EV To Sales33.0434.7840.5 K
Slightly volatile
Payables Turnover89.7385.4629.1434
Slightly volatile
Sales General And Administrative To Revenue1.922.02745
Slightly volatile
Research And Ddevelopement To Revenue6.326.652 K
Slightly volatile
Capex To Revenue0.150.16449
Slightly volatile
Cash Per Share6.879.35.0532
Slightly volatile
Days Payables Outstanding4.24.4248.6061
Slightly volatile
Net Debt To EBITDA0.330.350.5484
Slightly volatile
Current Ratio3.394.342.5783
Slightly volatile
Receivables Turnover0.140.160.1701
Slightly volatile
Capex Per Share0.09290.09780.1968
Slightly volatile
Revenue Per Share0.980.690.5305
Slightly volatile
Interest Debt Per Share1.381.770.9621
Slightly volatile
Debt To Assets0.210.170.2871
Slightly volatile
Operating Cycle1.7 K1.9 K2.1 K
Slightly volatile
Days Of Payables Outstanding4.24.4248.6061
Slightly volatile
Ebt Per Ebit1.311.041.116
Very volatile
Long Term Debt To Capitalization0.0040.00420.0272
Slightly volatile
Quick Ratio3.394.342.5783
Slightly volatile
Net Income Per E B T0.80.90.9791
Slightly volatile
Cash Ratio2.231.781.3086
Slightly volatile
Days Of Sales Outstanding1.7 K1.9 K2.1 K
Slightly volatile
Fixed Asset Turnover0.320.260.1767
Slightly volatile
Debt Ratio0.210.170.2871
Slightly volatile
Price Sales Ratio35.1136.9640.8 K
Slightly volatile
Asset Turnover0.0530.05180.0296
Slightly volatile

Beam Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.8 B2.4 B3.5 B
Slightly volatile
Enterprise Value3.6 B2.1 B3.4 B
Slightly volatile

Beam Fundamental Market Drivers

Beam Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Beam Therapeutics Financial Statements

Beam Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Beam Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue125.2 M63.7 M
Cost Of Revenue422.7 M211.8 M
Total Revenue73 M87.1 M
Stock Based Compensation To Revenue 2.18  2.08 
Sales General And Administrative To Revenue 2.02  1.92 
Research And Ddevelopement To Revenue 6.65  6.32 
Capex To Revenue 0.16  0.15 
Revenue Per Share 0.69  0.98 
Ebit Per Revenue(5.89)(6.18)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
How To Invest In Beam
Details
Is Beam Stock a good investment?
Details
What is Beam Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Beam Therapeutics Correlation against competitors.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.41)
Revenue Per Share
0.593
Quarterly Revenue Growth
(0.32)
Return On Assets
(0.23)
Return On Equity
(0.47)
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY